Overlapping Roles of JIP3 and JIP4 in Promoting Axonal Transport of Lysosomes in Human iPSC-Derived Neurons

Investigators established a hiPSC-derived neuron model for the investigation of axonal lysosome transport and maturation and showed that loss of JIP3 resulted in the accumulation of axonal lysosomes and the Alzheimer’s disease-related amyloid precursor protein-derived Aβ42 peptide.
[Molecular Biology of the Cell]
Gowrishankar, S., Lyons, L., Rafiq, N. M., Roczniak-Ferguson, A., De Camilli, P., & Ferguson, S. M. (2021). Overlapping roles of JIP3 and JIP4 in promoting axonal transport of lysosomes in human iPSC-derived neurons. Molecular Biology of the Cell, mbc.E20-06-0382. https://doi.org/10.1091/mbc.E20-06-0382 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Sex Differences in the Blood–Brain Barrier and Neurodegenerative Diseases

The authors describe sex-related differences in neurodegenerative diseases and the blood–brain barrier, whose dysfunction is linked to neurodegenerative disease development and progression.
[APL Bioengineering]
Weber, C. M., & Clyne, A. M. (2021). Sex differences in the blood–brain barrier and neurodegenerative diseases. APL Bioengineering, 5(1), 011509. https://doi.org/10.1063/5.0035610 Cite
Full ArticleEditorial
Bookmark

No account yet? Register

0
Share

Functional Neuromodulation Announces Breakthrough Device Designation from the US FDA for Deep Brain Stimulation for Alzheimer’s Disease

Functional Neuromodulation Ltd. announced that it has received Breakthrough Device designation from the Center for Devices and Radiological Health of the FDA for the Vercise Deep Brain Stimulation Systems, developed and manufactured by Boston Scientific Corporation, in the treatment of patients 65 years and older with mild probable Alzheimer’s disease.
[Functional Neuromodulation Ltd. (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease

Athira Pharma, Inc. announced that patient dosing has begun in ACT-AD, a Phase II randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule therapeutic designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in the central nervous system, in order to promote brain health and function.
[Athira Pharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Sigma Ligands As Potent Inhibitors of Aβ and AβOs in Neurons and Promising Therapeutic Agents of Alzheimer’s Disease

The authors review the pathophysiology of Alzheimer’s disease and highlight the sigma ligands that display the capability of preventing or even reversing amyloid-β (Aβ) – and amyloid-β oligomers (AβOs) -induced neurotoxicity and blocking the signal transduction caused by AβOs.
[Neuropharmacology]
Ma, W.-H., Chen, A.-F., Xie, X.-Y., & Huang, Y.-S. (2020). Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer’s disease. Neuropharmacology, 108342. https://doi.org/10.1016/j.neuropharm.2020.108342 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer’s Disease

Neurotrope, Inc.announced dosing of the first patient in its ongoing, long-term Phase II study of Bryostatin-1 for the treatment of Alzheimer’s disease. The study was conducted in collaboration with the National Institutes of Health under a $2.7 million grant to Neurotrope.
[Neurotrope, Inc. (PR Newswire LLC)]
Press Release
Bookmark

No account yet? Register

0
Share

The Effects of Microglia‐ and Astrocyte‐Derived Factors on Neurogenesis in Health and Disease

The authors describe how glial cells play a role in adult hippocampal neurogenesis in both health and disease, especially focusing on glia‐derived factors.
[European Journal of Neuroscience]
Abstract
Bookmark

No account yet? Register

0
Share

Attenuation of the Extracellular Matrix Restores Microglial Activity during the Early Stage of Amyloidosis

Two‐photon vital microscopy demonstrated normal morphology and resting motility of microglia but strongly diminished number of microglial cells that migrated to the photolesion site in 5xFAD mice.
[Glia]
Stoyanov, S., Sun, W., Düsedau, H. P., Cangalaya, C., Choi, I., Mirzapourdelavar, H., Baidoe‐Ansah, D., Kaushik, R., Neumann, J., Dunay, I. R., & Dityatev, A. (n.d.). Attenuation of the extracellular matrix restores microglial activity during the early stage of amyloidosis. Glia, n/a(n/a). https://doi.org/10.1002/glia.23894 Cite
Full Article
Bookmark

No account yet? Register

0
Share

UCB Enters into Collaboration with Roche to Develop Antibody Treatment for People Living with Alzheimer’s Disease

UCB today announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease.
[UCB]
Press Release
Bookmark

No account yet? Register

0
Share

AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase Ib/IIa Study

AC Immune SA announced the initiation of the second highest dosing group in the company’s Phase Ib/IIa clinical trial evaluating ACI-35.030 for the treatment of Alzheimer’s disease.
[AC Immune]
Press Release
Bookmark

No account yet? Register

0
Share

The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway

Investigators summarize and question what is known and remains to be discovered about the TREM2 signaling pathway, track the consequences of its activation in physiological niches and pathological contexts, and highlight the promising potential of therapeutic manipulation of TREM2 signaling.
[Cell]
Full Article

Bookmark

No account yet? Register

0
Share
Share